Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena
Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.
You may also be interested in...
Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.
Michael Buschle, Glenmark's chief scientific officer and president (biologics), clearly values the Indian firm's "entrepreneurial culture" and "flexibility", even if it means doing cutting edge R&D with relatively smaller budgets than Big Pharma enjoys.
Evolving strategies and competition appear to have contributed to significant tweaks on the Indian market for rituximab – currently in the spotlight with the entry of the local firm, Intas, with its biosimilar version of the monoclonal antibody.